{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001388","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.739018+00:00","generated_at":"2026-05-25T00:31:01.360394+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Anika completes sale of Parcus Medical for $4.5M cash, sharpens focus on OA pain management","bullets":["Sale closed March 7, 2025 to Medacta Group SA (Medacta Americas Manufacturing).","Cash consideration of $4.5M at closing, subject to customary post-closing adjustments.","Divestiture part of previously announced strategic review; company to focus on hyaluronic acid and regenerative solutions.","Parcus Medical was a wholly owned subsidiary; Anika received total cash consideration at closing.","Goodwin Procter served as legal counsel; Piper Sandler as exclusive financial advisor to Anika."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001388","json":"https://secwatch.observer/filing/0001171843-25-001388.json","markdown":"https://secwatch.observer/filing/0001171843-25-001388.md","text":"https://secwatch.observer/filing/0001171843-25-001388.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001388/0001171843-25-001388-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001388/f8k_031025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T00:31:01.360394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}